drugset / Trial / NCT00707993

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

NCT00707993

Phase 3 Completed 441 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.

Timeline

Start
2008-06
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 25 mg Oral
Comparator Glipizide Small molecule 5 mg Oral
Comparator Glipizide Small molecule 10 mg Oral